AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 388.63B, AbbVie(ABBV) trades at $219.76. The stock has a price-to-earnings ratio of 93.80 and currently yields dividends of 3.0%.
During the trading session on 2026-03-17, AbbVie(ABBV) shares reached a daily high of $223.28 and a low of $219.76. At a current price of $219.76, the stock is 0.0% higher than the low and still -1.6% under the high.
Trading volume for AbbVie(ABBV) stock has reached 4.4M, versus its average volume of 6.45M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
Key Points AbbVie has an extensive pipeline of potential drugs and medical devices. Walmart's growing dividend is a nice addition to its big stock-price gain....
Alloy Therapeutics announced an agreement with AbbVie (ABBV) to develop a new antibody platform to discover potent, specific, and effective antibodies against t...
Earlier this month, AbbVie reported positive Phase 1 multiple-ascending-dose results for its investigational obesity drug ABBV-295, a long-acting amylin analog...
Analyst ratings
67%
of 33 ratingsMore ABBV News
Advertisement What AbbVie’s Recent Performance Tells You Right Now AbbVie (ABBV) has drawn investor attention after a period of weaker share performance, with...
UCB reported that its arthritis drug Bimzelx outperformed AbbVie’s Skyrizi in a head to head clinical trial in psoriatic arthritis. The trial result introduces...
Abbvie (ABBV) announced an update on their ongoing clinical study. The phase 1 study, officially titled “A Phase 1 Study in Healthy Subjects to Assess Pharmaco...
Key Points AbbVie can maintain solid financial results even during recessions. Microsoft's vast and loyal client base and strong growth prospects make it a st...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.